Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

Time has come.

When a person suffers a cardiac arrest, it is still generally assumed that within a few minutes first the brain and then also the other organs are so severely damaged that there is a narrow time frame beyond which there is as small chance of successful resus­citation.

Time limit of saving heart and brain with conventional methods.
The Next Level of ECPR.
Personalized and Controlled Resuscitation.

To shift the Limits.

Recent research shows that this assumption is not true: The organs and also the brain can survive much longer without the supply of oxygen. But the entire body is in a special state that must be understood very precisely and treated on a patient-specific basis.

CARL is designed for this particular patient state after cardiac arrest and aims to push the current limits of resuscitation by improving neurological-intact survival through individualized and targeted resuscitation.

CARL. The Next Level of ECPR.

CARL Therapy focuses on controlled reperfusion during extracorporeal resuscitation (ECPR), in which key vital parameters are monitored on a patient- and situation-specific basis, thereby potentially increasing the chance of neurologically intact survival. To ensure the optimal application of the therapy, the CARL Technology was developed specifically for resuscitation use. All-day clinical support as well as an extensive training program through the CARL Academy are available online or at on-site facilities to clinical users at all times.


What experts say.

Univ. Prof. Dr. Dr. h. c. Friedhelm Beyersdorf

“We have developed a novel therapy for resuscitation from the findings of our years of clinical research, which we call CARL Therapy. The new therapy is based on extracorporeal circulation, through which the organism damaged by the cardiac arrest is additionally treated. During a CARL therapy – and this is new – numerous values are measured that provide information about the patient’s condition. The patient’s treatment is targeted accordingly by adjusting the flow, composition and temperature of the blood to his or her individual needs.”

Univ. Prof. Dr. Dr. h. c. Friedhelm Beyersdorf
Founder & Initiator
Former Medical Director of the Clinic of Cardiovascular Surgery at the Medical Center – University of Freiburg

Prof. Dr. Trummer

“With the newly developed CARL Therapy, we hope to be able to shift the previous limits of resuscitation. It is the first personalized therapy that takes into account the individual condition of a cardiac arrest patient and in this way helps to prevent cell and organ damage of the kind that occurs after blood flow is restored.”

Prof. Dr. Georg Trummer
Clinic for Cardiovascular Surgery I Department University Heart Center I Freiburg University Hospital

Prof. Dr.-Ing. Benk

“In order to establish CARL Therapy in clinical practice, numerous innovative approaches in the field of medical technology were required. The visionary challenge was to be able to automatically control and thus monitor both the physical and biochemical perfusion conditions during extracorporeal circulation, and to do so during emergency operations both in and outside the hospital.

We have risen to this challenge – and today we have reached the point where our smart system can start its journey into the clinics.”

Prof. Dr.-Ing. Christoph Benk
Managing Director I Resuscitec GmbH

Back to life.

Retiree back to life after cardiac arrest

Learn more >

31-year-old man survives cardiac arrest without neurological sequelae

Learn more >

Family man survives thanks to CARL.

Learn more >

37 year old woman resuscitated after long-term cardiac arrest without neurological damage.

Learn more >

Mid-forty shows no neurological impairment after prolonged circuit bridging with CARL.

Learn more >

Mid-40s woman discharged after heart failure without impaired brain function thanks to personalized CARL therapy.

Learn more >